GC Genome Corporation (KOSDAQ:340450)
8,000.00
+380.00 (4.99%)
Nov 18, 2026, 3:30 PM KST
GC Genome Revenue
GC Genome had revenue of 8.29B KRW in the quarter ending June 30, 2026, with 6.17% growth. This brings the company's total for the last twelve months to 32.64B, up 13.71% year-over-year. In the year 2025, GC Genome had annual revenue of 31.53B with 21.81% growth. That makes GC Genome the 32,688th largest company in the world by revenue and 2,084th in South Korea.
Revenue (ttm)
32.64B
Revenue Growth
+13.71%
P/S Ratio
5.65
Revenue / Employee
n/a
Employees
n/a
Market Cap
189.21B
Revenue by Segment
Fiscal year ended Dec 31, 2024 See the full GC Genome breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.53B | 5.65B | 21.81% |
| Dec 31, 2024 | 25.89B | -1.40B | -5.15% |
| Dec 31, 2023 | 27.29B | 3.18B | 13.18% |
| Dec 31, 2022 | 24.11B | 5.62B | 30.36% |
| Dec 31, 2021 | 18.50B | 4.94B | 36.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bioneer | 345.88B |
| GC Cell | 162.00B |
| MEDIPOST | 74.84B |
| HLB Therapeutics | 64.45B |
| SillaJen | 10.77B |
| Anterogen.Co.,Ltd. | 9.29B |
| NeoImmuneTech | 6.60B |
| MedPacto | 4.99B |